Fisetin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Fisetin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Fisetin.
Dosing Protocols
Beginner protocol — introduction to fisetin for antioxidant support and early senolytic application:
Step 1: Clarify goals. Fisetin supplementation is typically approached for (a) general antioxidant and anti-inflammatory support; (b) senolytic applications targeting age-related cellular senescence; (c) neuroprotective applications for cognitive aging; or (d) osteoarthritis, sarcopenia, or other age-related conditions. The dose and protocol differ substantially between these goals.
Step 2: For general antioxidant and anti-inflammatory support, begin at 100 mg daily of a bioavailability-enhanced fisetin (phytosome or Novusetin) with a fat-containing meal. Continue for 4-8 weeks to assess tolerability and any early subjective effects.
Step 3: Build dietary polyphenol foundation — incorporate strawberries (the richest dietary fisetin source, approximately 20-25 mg per cup), apples with peel, berries, onions, green tea, and other polyphenol-rich foods regularly. Dietary fisetin is modest compared to supplementation doses but supports gut microbiota polyphenol metabolism.
Step 4: For early senolytic supplementation without requiring prescription or high-dose pulses, continue fisetin 100-200 mg daily of a bioavailability-enhanced form combined with quercetin 500 mg daily (EMIQ or phytosome) for 4-8 weeks. Assess tolerability and consider escalating to pulse-dose senolytic protocol if desired.
Step 5: For users interested in senolytic pulse dosing, the AFFIRM-LITE-style protocol is the reference standard: 20 mg/kg for 2 consecutive days monthly. For a 70-kg adult, this is approximately 1400 mg per day for 2 consecutive days each month. Administer with food on each day, ideally with some dietary fat. Add quercetin 500-1000 mg during pulse days for complementary effect.
Step 6: Monitor for expected and unexpected effects. Mild transient fatigue, GI effects, or headache on pulse days are common and self-limited. Serious adverse effects are rare at this dosing. If significant symptoms emerge, reduce dose or consult a clinician.
Step 7: Integrate with broader lifestyle foundation — exercise (aerobic and resistance), adequate sleep, Mediterranean or similar polyphenol-rich dietary pattern, stress management. Senolytic supplementation works best as part of comprehensive lifestyle interventions rather than in isolation.
Intermediate protocol — specific clinical applications:
Step 1: Osteoarthritis adjunctive management — fisetin 100-200 mg daily continuously combined with standard OA support (glucosamine, chondroitin, MSM, curcumin, boswellia, omega-3). Pulse-dose senolytic protocol (20 mg/kg for 2 days monthly) as additional intervention. Coordinated with orthopedic or rheumatology care. Clinical trials in knee OA are underway; this is investigational adjunctive therapy.
Step 2: Mild cognitive impairment and cognitive aging — fisetin 100-200 mg daily continuously combined with neuroprotective stack (lion's mane, curcumin phytosome, bacopa, omega-3 DHA-rich, citicoline, magnesium L-threonate, creatine). Consider pulse-dose senolytic protocol if appropriate. Neurology or neuropsychological evaluation provides objective cognitive tracking. Evidence is preclinical and early clinical; this is investigational use.
Step 3: Frailty and sarcopenia — fisetin pulse-dose protocol (20 mg/kg for 2 days monthly) with optional continuous low-dose maintenance. Combined with resistance exercise, adequate protein intake (1.2-1.6 g/kg/day), vitamin D3 replete status, creatine 3-5 g daily, and other sarcopenia-directed nutrition. Geriatric or functional medicine oversight appropriate.
Step 4: Diabetic kidney disease adjunctive support — Hickson 2019 (PMID 31542391) tested D+Q senolytic in this population with reduced adipose tissue senescent cell markers. Fisetin alone has not been specifically tested in this indication but is being used by some clinicians as part of a longevity-focused approach. Coordinate with nephrology.
Step 5: Post-COVID fatigue and long COVID — fisetin 1500 mg daily for 14 days (Lloret-Villas 2021 pilot dosing) or pulse-dose senolytic protocol monthly. Clinical evidence is preliminary. Combine with addressing specific long COVID symptoms (cognitive, cardiovascular, pulmonary) as appropriate.
Step 6: General longevity supplementation — fisetin 100-200 mg daily maintenance plus 20 mg/kg for 2 days monthly senolytic pulse as part of comprehensive longevity stack. Reassess annually with biomarker panel (comprehensive metabolic, lipid, inflammation markers including hs-CRP, IL-6, HbA1c, fasting insulin, etc.) and functional assessments.
Step 7: Preoperative conditioning in older adults — emerging literature suggests that senolytic interventions prior to major surgery may reduce postoperative senescence-associated recovery challenges. This is investigational; discuss with surgical team before use.
Step 8: Cancer survivorship (in patients in remission and cleared by oncology) — fisetin maintenance and intermittent senolytic dosing may be considered as part of survivorship care but requires oncology specialist clearance. Active cancer or recent chemotherapy should involve specific oncologic guidance; fisetin's chemotherapy-modulating effects are mechanism-dependent.
Advanced protocol — research-informed high-dose and specialist applications:
Step 1: Dose titration based on body weight — fisetin 20 mg/kg for 2 consecutive days monthly has become the standard senolytic pulse protocol, scaled from the Yousefzadeh 2018 mouse studies through allometric adjustment to human dosing. For a 70-kg adult, 1400 mg per day for 2 days; for a 90-kg adult, 1800 mg per day for 2 days; for a 55-kg adult, 1100 mg per day for 2 days. Scale according to actual body weight rather than using fixed mg doses.
Step 2: Combination senolytic protocols — some advanced protocols alternate fisetin pulse with D+Q (dasatinib + quercetin) pulse on alternating months. Rationale is that different senolytic agents may target different senescent cell subtypes more efficiently. D+Q requires prescription dasatinib; alternating months provides broader senescent cell coverage while limiting cumulative chemotherapy exposure.
Step 3: Phytosome versus aglycone choice — for pulse dosing at 1400-1800 mg, phytosome formulations provide substantially higher plasma concentrations and may improve senolytic efficacy. Standard aglycone is acceptable but less well-characterized for clinical response. Quercefit or proprietary fisetin phytosome formulations are worth the price premium for senolytic applications.
Step 4: Biomarker monitoring for advanced users — baseline assessment of age-related biomarkers (DNA methylation clocks: Horvath, Hannum, PhenoAge, GrimAge; plasma inflammatory markers: IL-6, hs-CRP, TNF-alpha; senescence markers: p16INK4a in PBMCs if available through research lab; epigenetic age acceleration). Reassess annually to track biomarker response to senolytic intervention. Not routinely clinical but useful for research-oriented users.
Step 5: Sarcopenia biomarkers — appendicular lean mass (DXA), grip strength, walking speed, SPPB (Short Physical Performance Battery). Baseline assessment and annual follow-up allow objective response tracking.
Step 6: Integration with rapamycin (prescription mTOR inhibitor) — some longevity-focused protocols combine rapamycin (typically 5-10 mg weekly for adults) with fisetin pulse senolytic. Rapamycin addresses mTOR-driven cellular and organismal aging; senolytics address cellular senescence. The two mechanisms are complementary. Requires prescribing physician (some concierge medicine and longevity clinics offer rapamycin for non-transplant longevity indications). Drug interactions and individualized dosing important.
Step 7: Cycling and duration considerations — standard senolytic pulse protocols are monthly or quarterly. Longer intervals (every 3 months) may be sufficient for relatively healthy adults; shorter intervals (biweekly or monthly) are used in accelerated aging contexts or advanced disease. No definitive evidence supports any particular cycling frequency; AFFIRM-LITE monthly dosing is the reference standard.
Step 8: Genetic variant considerations — COMT, UGT, and SULT variants affect fisetin metabolism through Phase II conjugation. Generally not actionable clinically but relevant in research contexts.
Step 9: Age and starting population — fisetin's strongest preclinical effects are in aged mice, not young mice. Starting senolytic protocols in very young individuals (<40) may have limited benefit because senescent cell burden is low. Starting age 50-60+ with established risk factors or age-related conditions may offer better benefit-risk ratio.
Step 10: Integration with caloric restriction, time-restricted eating, and exercise — senolytic pulse dosing combined with lifestyle interventions targeting autophagy (time-restricted eating, fasting-mimicking diet periodic cycles, regular aerobic and resistance exercise) provides comprehensive pro-longevity approach. Lifestyle foundation amplifies supplementation effects and is prerequisite to expected benefit.
Step 11: Long-term monitoring and reassessment — annual clinical evaluation including cognitive, physical function, metabolic, cardiovascular, and oncologic surveillance. Adjust protocol based on biomarker and functional response, emerging trial evidence, and individual tolerability.
Commonly Stacked With
Fisetin stacks with multiple longevity, senolytic, neuroprotective, and general antioxidant compounds in integrated protocols.
For senolytic stacking, fisetin is classically paired with its closely related flavonoid quercetin. On fisetin pulse-dose days (typically 2 consecutive days monthly at 20 mg/kg), many protocols add quercetin 500-1000 mg for complementary and additive senolytic effect. Some practitioners use alternating fisetin and D+Q (dasatinib + quercetin) pulse protocols to target different senescent cell subtypes. The combination fisetin + quercetin without prescription dasatinib provides a non-prescription self-administered senolytic option with favorable safety and reasonable preclinical support.
For the longevity and healthspan stack, fisetin combines with rapamycin (prescription mTOR inhibitor at intermittent dosing — the most thoroughly validated anti-aging intervention), spermidine 1-5 mg daily (autophagy induction), NMN or nicotinamide-riboside 250-1000 mg daily (NAD precursors), resveratrol 250-500 mg or pterostilbene 100-250 mg (stilbene polyphenols with SIRT1 activation), curcumin 500-1000 mg phytosome (polyphenol anti-inflammatory), CoQ10 100-200 mg and/or MitoQ (mitochondrial targeting), omega-3 2-4 g daily, vitamin-d3 2000-5000 IU, vitamin-k2 MK-7 100-200 mcg, magnesium 200-400 mg glycinate, and standard multivitamin/mineral foundation. This comprehensive stack addresses multiple aging hallmarks simultaneously.
For neurodegenerative and cognitive applications, fisetin combines with lion's mane 1-3 g daily (NGF/BDNF support), curcumin phytosome (Aβ aggregation), bacopa 300-600 mg (memory support), phosphatidylserine 100-300 mg, citicoline 250-500 mg, acetyl-l-carnitine 1-2 g, omega-3 with emphasis on DHA, magnesium-l-threonate 1-2 g, and creatine 3-5 g daily (cognitive energetics). This stack addresses multiple pathways in cognitive aging.
For osteoarthritis and musculoskeletal senescence, fisetin combines with glucosamine 1500 mg and chondroitin 1200 mg (joint matrix support), MSM 1-3 g, curcumin phytosome, boswellia 400-600 mg (AKBA-standardized), collagen peptides 10-20 g daily, vitamin-c, and omega-3. The senolytic pulse dosing targets chondrocyte senescence while the maintenance stack supports joint matrix homeostasis.
For anti-inflammatory and antioxidant stacking, fisetin combines with curcumin phytosome, quercetin, resveratrol, pterostilbene, EGCG green tea extract, pycnogenol, grape-seed-extract, astaxanthin, and milk-thistle silymarin. This polyphenol-dominant stack provides broad tissue coverage.
For metabolic health and glycemic support, fisetin combines with berberine 500 mg three times daily, alpha-lipoic-acid 300-600 mg, chromium 200-600 mcg, magnesium, cinnamon extract, and appropriate glucose monitoring.
For cardiovascular prevention and endothelial support, fisetin combines with CoQ10, omega-3, vitamin-k2, magnesium, L-citrulline, taurine, resveratrol, and quercetin.
Dietary enhancement strategies:
-
Dietary fat co-consumption — fisetin is lipophilic and absorption is enhanced by dietary fat. Take with meals containing olive oil, avocado, nuts, or other fat sources.
-
Bioavailability-enhanced formulations — fisetin phytosome (sunflower lecithin complex) or Novusetin standardized aglycone with fat-containing meal. Some brands add piperine (black pepper extract) for absorption enhancement.
-
Co-consumption with quercetin — the two flavonoids may enhance each other's bioavailability through competitive Phase II conjugation and overlapping tissue distribution.
-
Dietary foundation of polyphenol-rich foods — berries (especially strawberries), apples, onions, green tea, cocoa, extra virgin olive oil, dark chocolate. Supports gut microbiota that produce fisetin's bioactive metabolites.
-
Avoiding absorption competitors — cholestyramine, orlistat, and fat malabsorption syndromes reduce fisetin uptake. Time-separate as needed.
Timing recommendations:
For continuous daily dosing (maintenance 100-200 mg daily), take with the largest fat-containing meal of the day.
For senolytic pulse dosing (20 mg/kg for 2 consecutive days monthly), administer on 2 consecutive days each month at a consistent time (e.g., morning of day 1 and morning of day 2 of a designated monthly pulse window). Co-administer quercetin 500-1000 mg during pulse days if desired. Take with fat-containing meal for optimal absorption.
Stacks to avoid or time-separate:
- Tyrosine kinase inhibitor chemotherapy (non-senolytic contexts) — specialist required.
- Fluoroquinolone antibiotics — separate by 2-4 hours or suspend fisetin during active antibiotic courses.
- Warfarin — monitor INR when initiating.
- Iron supplementation — separate by 2-4 hours.
- Simultaneous high-dose quercetin (non-senolytic maintenance) — no specific concern; can co-administer.
Canonical recommendation for longevity-focused users: maintenance fisetin 100-200 mg daily of a bioavailability-enhanced form (phytosome or Novusetin with fat) plus senolytic pulse at 20 mg/kg for 2 consecutive days monthly (approximately 1400-1600 mg per day for 2 days for a 70-kg adult), paired with quercetin 500-1000 mg on pulse days, embedded in a broader longevity stack (NMN/NR, rapamycin under prescription supervision, spermidine, resveratrol or pterostilbene, omega-3, vitamin D3, vitamin K2, magnesium). Reassess annually in context of health goals and laboratory/functional markers.
Side Effects & Safety
Contraindications
Contraindications for fisetin supplementation are generally relative rather than absolute, with favorable safety across both continuous maintenance dosing and intermittent pulse-dose protocols. Absolute contraindications: None established in typical adults at standard supplementation doses. Fisetin has an exceptionally favorable safety profile in preclinical and clinical studies. Relative contraindications and caution situations: Tyrosine kinase inhibitor chemotherapy (non-senolytic context) — fisetin has intrinsic tyrosine kinase modulation. The intentional D+Q combination with dasatinib for senolytic purposes is clinically recognized; other combinations require oncology specialist supervision. Warfarin anticoagulation — fisetin has mild antiplatelet activity and potential CYP2C9 modulation (less pronounced than quercetin). Monitor INR at 1-2 weeks after starting fisetin or after initiating pulse-dose protocol. Fluoroquinolone antibiotics — potential antagonism of antibacterial activity. Separate doses by 2-4 hours or suspend fisetin during active fluoroquinolone therapy. Chemotherapy agents — fisetin's mTOR inhibition, autophagy induction, and P-glycoprotein modulation may affect chemotherapy exposure or efficacy. Oncology specialist required. CYP3A4-metabolized drugs at high pulse doses — possible interactions with statins, some antihypertensives, and some protease inhibitors. Usually not clinically significant at typical maintenance doses but review at pulse-dose levels. P-glycoprotein substrates (digoxin, some chemotherapy) — potential modest increase in exposure through P-gp inhibition. Monitor if both are required. Antiplatelet medications (aspirin, clopidogrel) — additive bleeding risk; usually not clinically significant at standard doses. Pregnancy — dietary intake through strawberries and other natural sources is unambiguously safe. Supplementation at maintenance or pulse doses during pregnancy has limited safety data. Conservative practice is to rely on dietary intake and avoid supplementation during pregnancy without specific medical indication. Lactation — limited data at supplementation doses. Dietary intake is safe. Pediatric use — not routinely indicated for healthy children. Specific pediatric indications (neurodegenerative syndromes, certain cancer adjunct contexts) may warrant supplementation under specialist supervision. Hepatic impairment — conjugation is reduced in severe liver disease potentially altering pharmacokinetics. No established hepatotoxicity. Use moderate doses and monitor clinical response. Renal impairment — no specific renal toxicity. Severe CKD (stage 4-5) may warrant dose reduction due to altered clearance and lack of specific PK data in this population. Active peptic ulcer disease — the mild antiplatelet effect may warrant caution in the presence of bleeding ulcer. Usually not a significant clinical concern but avoid during active GI bleeding contexts. Hormone-sensitive cancers — fisetin has weak phytoestrogenic activity (less than quercetin). Theoretical caution exists in active estrogen-sensitive cancers. Specialist consultation warranted before high-dose or pulse-dose supplementation in this context. Surgery — the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Resume after surgical recovery. Severe or uncontrolled hypertension — fisetin has modest blood pressure effects. Monitor but usually not a contraindication. Extremely high-dose protocols (beyond 20 mg/kg for 2 days monthly) — long-term safety at doses exceeding the AFFIRM-LITE reference is less characterized. Conservative practice is to use established dosing protocols rather than improvising higher doses. Recent stroke or bleeding disorder — the mild antiplatelet effect may warrant caution. Coordinate with neurology or hematology. Strawberry allergy — most commercial fisetin is extracted from Rhus succedanea or Acacia, not strawberries. Strawberry allergy is not typically a concern for fisetin supplementation. Synthetic fisetin is also available. Known allergy to supplement excipients — capsule materials, fillers, or phytosome lecithin components may cause reactions in sensitive individuals. Specific clinical situations warranting specialist guidance: - Active cancer or recent chemotherapy — coordinate with oncology. - Solid organ transplant recipients — coordinate with transplant team; immunosuppressive drug interactions may occur. - Multiple medications with CYP3A4 or P-gp involvement — review interaction potential before adding fisetin. - Pregnancy and fertility treatment — avoid supplementation; dietary intake safe. - Severe renal or hepatic impairment — reduce dose and monitor clinical response. - Bleeding disorders or current anticoagulation — coordinate with hematology. Overall, fisetin supplementation at continuous maintenance doses of 100-200 mg daily or intermittent pulse doses of 20 mg/kg for 2 consecutive days monthly in most adults has a favorable risk-benefit profile. The main practical considerations are drug interactions (anticoagulants, tyrosine kinase inhibitor chemotherapy, fluoroquinolones), surgical bleeding risk, limited pregnancy data, and the need for specialist supervision in oncology and complex medication contexts. The D+Q combination with prescription dasatinib requires specialist medical supervision and is not self-administered.
Additional Notes
Standard maintenance dose: Fisetin 100-200 mg daily of a bioavailability-enhanced form (phytosome or Novusetin standardized) with a fat-containing meal.
Senolytic pulse-dose protocol (AFFIRM-LITE standard): 20 mg/kg for 2 consecutive days monthly. For 70-kg adult, approximately 1400 mg per day for 2 days. Scale proportionally to actual body weight.
Senolytic pulse quarterly protocol: same 20 mg/kg for 2 consecutive days, every 3 months rather than monthly. May be sufficient for healthy adults without age-related conditions.
Osteoarthritis adjunctive dose: 100-200 mg daily maintenance plus monthly pulse.
Cognitive aging dose: 100-200 mg daily maintenance; consider monthly pulse for advanced protocols.
Dietary equivalents:
- 1 cup strawberries (150 g): 24 mg fisetin
- 1 medium apple: 3-5 mg
- 100 g persimmon: 1 mg
- 100 g lotus root: 0.6 mg
- 100 g onion: 0.5 mg
- Typical Western daily intake: less than 1 mg
Timing: Plasma half-life 3-5 hours for aglycone, up to 9 hours for glucuronide metabolite. Daily maintenance doses can be taken once daily with main meal. Pulse doses on 2 consecutive days are typically taken once daily with main meal of each day, though splitting into morning and evening doses reduces GI complaints in some users.
Duration: Continuous maintenance dosing for long-term indefinite use is generally well-tolerated. Pulse-dosing on a monthly or quarterly schedule is the reference senolytic protocol.
Cooking and food preparation: Fisetin is heat-stable. Cooked strawberry sauces (not common) would retain fisetin. Dietary sources are primarily raw fruits.
Pediatric use: Not routinely indicated. Dietary intake through food is safe.
Pregnancy: Dietary intake is safe. Supplementation data limited; high-dose use during pregnancy should be discussed with obstetrician.
Lactation: Safe at dietary intake levels. Supplementation data limited.
Geriatric use: This is the primary demographic for senolytic use. Dose by body weight as with younger adults; no specific age-based adjustment. Ensure adequate dietary fat at dosing for absorption.
Renal impairment: No formal dose adjustment. Severe CKD may warrant reduced dose or increased interval between pulses; specific PK data in this population are limited.
Hepatic impairment: Hepatic conjugation is reduced in severe liver disease; may affect pharmacokinetics. Monitor clinical response. No specific dose adjustment established.
Drug interactions (dose-relevant):
- Tyrosine kinase inhibitor chemotherapy: specialist required for combination.
- Warfarin: monitor INR.
- Fluoroquinolones: time-separate by 2-4 hours.
- Iron supplementation: time-separate by 2-4 hours.
- Cholestyramine/orlistat: time-separate by 2-4 hours.
Brand notes:
- Novusetin (HealthStar): standardized 98% fisetin aglycone ingredient, used in multiple commercial products.
- Fisetin phytosome (proprietary formulations): sunflower lecithin complex with 3-5-fold bioavailability enhancement.
- Doctor's Best: aglycone products widely available.
- Thorne Research, Designs for Health, Pure Encapsulations: reputable manufacturers with quality control.
- Avoid unknown-origin products or deeply discounted unverified brands. Confirm form (aglycone, phytosome) on label.
Common mistakes: (1) Taking on empty stomach — reduces absorption substantially. (2) Using non-enhanced aglycone for pulse-dose senolytic protocol — may not reach effective plasma concentrations. (3) Skipping the pulse dosing pattern in favor of continuous daily high dose — the reference protocol is intermittent pulses, not continuous high-dose use. (4) Underdosing based on fixed mg rather than body weight — scale proportionally. (5) Expecting immediate effects from senolytic pulse — biomarker and functional responses emerge over months to years of sustained protocol adherence. (6) Failing to combine with lifestyle foundation (exercise, sleep, diet) — supplementation alone is insufficient.
Frequently Asked Questions
What is the recommended Fisetin dosage?
Dosage for Fisetin varies by protocol. Consult a qualified healthcare provider.
How often should I take Fisetin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Fisetin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Fisetin side effects?
Fisetin has a highly favorable safety profile in both preclinical and emerging clinical data, with minimal serious adverse events reported at typical supplementation doses and acceptable tolerability at high pulse-dose senolytic protocols. Gastrointestinal tolerance: generally excellent. Mild transient nausea, loose stools, or gastric discomfort at high doses (1000+ mg per dose) in a minority of users. Taking with food eliminates most complaints. Dividing a pulse dose (e.g., 1500 mg split into morning and evening doses on pulse days) reduces GI complaints compared to single bolus dosing. Headache: uncommon, typically mild and transient when reported. Usually occurs at initiation of high-dose supplementation and resolves within 24-48 hours. Orange-yellow urine discoloration: occasional at high doses due to excretion of fisetin metabolites. Harmless and resolves with reduced intake. Fatigue: some users report transient fatigue on senolytic pulse-dosing days, potentially reflecting the biological activity of senescent cell clearance. Usually mild and resolves 1-3 days after completing the pulse. Flushing: rare, transient, typically during initial pulse-dose exposure. Paresthesia (tingling): extremely rare. Reversible on dose reduction. Drug interactions — fewer clinically significant than quercetin but still warrant attention: - Tyrosine kinase inhibitor chemotherapy (dasatinib, imatinib, erlotinib, gefitinib): fisetin has intrinsic tyrosine kinase modulation and may produce unintended additive effects. The intentional D+Q combination with dasatinib is clinically relevant for senolytic applications; other combinations require oncology specialist supervision. - Warfarin and anticoagulants: fisetin has mild antiplatelet activity and potential CYP2C9 modulation. Effect is smaller than for quercetin. Monitor INR when initiating fisetin supplementation during warfarin therapy. - Fluoroquinolone antibiotics: fisetin binds DNA gyrase at the same binding site as fluoroquinolones, potentially antagonizing antibacterial activity. Separate doses by 2-4 hours or avoid during active fluoroquinolone therapy. - Some CYP3A4-metabolized drugs: fisetin may modestly inhibit CYP3A4. Clinically significant interactions are uncommon at typical doses but possible at pulse-dosing senolytic levels (1000+ mg per dose). Review medication list. - P-glycoprotein substrates (digoxin, some chemotherapy agents): potential modest interaction through P-gp inhibition. Monitor if both are required. - Chemotherapy agents generally: oncology patients should discuss fisetin supplementation with their oncologist. The mTOR-inhibitory and autophagy-inducing effects have theoretical implications for chemotherapy synergy or antagonism. - Antihypertensive medications: fisetin has modest cardiovascular effects; monitor blood pressure when initiating, though clinically significant interactions are rare. - Iron supplementation: chelation reduces iron absorption. Separate by 2-4 hours if both are being actively supplemented. Pregnancy: human safety data at supplementation doses are limited. Dietary intake through strawberries and other natural sources is unambiguously safe. High-dose supplementation during pregnancy is generally avoided in the absence of specific medical indication. Lactation: limited data. Dietary intake is safe. Supplementation data are limited. Pediatric use: not indicated for routine use in healthy children. Specific pediatric conditions (neurodegenerative syndromes, childhood cancer adjunct) may warrant supplementation under specialist supervision. Senolytic pulse-dosing safety considerations: At the AFFIRM-LITE protocol of 20 mg/kg for 2 consecutive days monthly, pilot human data show the protocol is well-tolerated with no dose-limiting toxicity. Mild transient fatigue, GI effects, or headache on pulse days are the most commonly reported. The intermittent nature of senolytic pulses minimizes cumulative exposure and allows tissue recovery between pulses. At very high doses (3000+ mg daily for multiple consecutive days), the safety profile is less well-characterized. Conservative practice uses the AFFIRM-LITE-style protocol (20 mg/kg for 2 consecutive days monthly) rather than higher or more sustained dosing. Liver function: not associated with fisetin at any tested dose. No consistent signal of liver enzyme elevation. Renal function: not associated with fisetin. No specific renal dose adjustment. Patients with severe CKD stage 4-5 may warrant dose reduction in the absence of specific PK data in that population. Cardiovascular: fisetin has modest favorable effects on endothelial function and blood pressure. No arrhythmogenic concerns. Patients with severe cardiovascular disease should discuss supplementation with their cardiologist. Hematologic: mild antiplatelet activity is present but less pronounced than for aspirin or prescription antiplatelets. Discontinue 2 weeks before scheduled surgery as a precaution. Hormone-sensitive cancers: fisetin has weak phytoestrogenic activity. Theoretical caution in active estrogen-sensitive cancers; dietary intake is acceptable; specialist consultation warranted before high-dose or pulse-dose supplementation. Autoimmune disease: fisetin's anti-inflammatory and immune-modulating effects are generally favorable. No specific contraindications in most autoimmune conditions. Surgery: the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Extremely high-dose research protocols: fisetin has been tested up to 500 mg/kg in mice with good tolerability. Human scaling has been conservative, with pulse doses at 20 mg/kg the most commonly used protocol and continuous dosing typically limited to 100-500 mg daily. Allergic reactions: fisetin itself is not a common allergen. Strawberry-derived fisetin supplements are rare (most commercial fisetin is from Rhus or synthetic) so strawberry allergy is not typically a concern. Supplement excipients (capsule materials, fillers) may cause reactions in sensitive individuals. Long-term safety: animal studies in aged mice up to 10 months of intermittent pulse dosing have not identified safety concerns. Human long-term data from AFFIRM-LITE and subsequent trials are still accumulating but early signals are favorable. Overall, fisetin supplementation at doses of 100-500 mg daily continuously or 20 mg/kg for 2 consecutive days monthly (approximately 1400-1600 mg for an average adult) is well-tolerated in most users. The main practical considerations are drug interactions (anticoagulants, fluoroquinolones, tyrosine kinase inhibitors, chemotherapy), surgical bleeding risk, and the theoretical need for specialist supervision in oncology and complex medication contexts. The risk-benefit profile is favorable for most adult users interested in senolytic or longevity-focused supplementation.
Where can I buy Fisetin?
Visit our vendor directory to find trusted sources for Fisetin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
